Miraculins Nets $405K in Private Stock Placement | GenomeWeb
NEW YORK (GenomeWeb News) — Miraculins said yesterday it has pocketed CA$428,000 ($405,000) in a private stock placement by selling 1,222,858 units of certain shares at CA$.35 apiece.
 
The company said in July it could earn as much as CA$500,000 total from the sale by selling 1.25 million units at CA$.40 apiece.
 
Miraculins plans to use the money to fund research and development projects and to replenish working capital coffers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.